Noruega -
noruego -
Statens legemiddelverk
metoprolol sandoz 200 mg
sandoz as - metoprololsuksinat - depottablett - 200 mg
Noruega -
noruego -
Statens legemiddelverk
solu-medrol 125 mg
pfizer as - metylprednisolonnatriumsuksinat - pulver og væske til injeksjonsvæske, oppløsning - 125 mg
Noruega -
noruego -
Statens legemiddelverk
solu-medrol 1 g
pfizer as - metylprednisolonnatriumsuksinat - pulver og væske til injeksjonsvæske, oppløsning - 1 g
Noruega -
noruego -
Statens legemiddelverk
solu-medrol 40 mg
pfizer as - metylprednisolonnatriumsuksinat - pulver og væske til injeksjonsvæske, oppløsning - 40 mg
Noruega -
noruego -
Statens legemiddelverk
solu-medrol 500 mg
pfizer as - metylprednisolonnatriumsuksinat - pulver og væske til injeksjonsvæske, oppløsning - 500 mg
Noruega -
noruego -
Statens legemiddelverk
topiramat bluefish 200 mg
bluefish pharmaceuticals ab - topiramat - tablett, filmdrasjert - 200 mg
Noruega -
noruego -
Statens legemiddelverk
topiramat bluefish 25 mg
bluefish pharmaceuticals ab - topiramat - tablett, filmdrasjert - 25 mg
Noruega -
noruego -
Statens legemiddelverk
topiramat bluefish 50 mg
bluefish pharmaceuticals ab - topiramat - tablett, filmdrasjert - 50 mg
Noruega -
noruego -
Statens legemiddelverk
topiramat bluefish 100 mg
bluefish pharmaceuticals ab - topiramat - tablett, filmdrasjert - 100 mg
Unión Europea -
noruego -
EMA (European Medicines Agency)
brukinsa
beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastiske midler - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).